Faculty

Barry J. Make, MD, FACP, FCCP, FACVPR
Professor, Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, Colorado

Barbara P. Yawn, MD, MSc, FAAFP
Adjunct Professor, Department of Family and Community Health
University of Minnesota
Minneapolis, Minnesota

Course Description

This CME-accredited CME Snapshot™ educational series is intended for primary care clinicians and other health care providers involved in the ongoing management of patients with chronic obstructive pulmonary disease (COPD). Within each focused activity, an expert pulmonologist and a primary care educator discuss best practices for a specific aspect of managing patients with COPD, including monitoring the disease course over time, maximizing patient function, and individualizing treatment regimens. One activity also addresses patients’ perspectives by incorporating patient-clinician interactions and insights into disease burdens, challenges to good long-term outcomes, and shared decision-making.

Target Audience

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with COPD.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Communicate with patients and their caregivers about the need for exacerbation action plans, treatment adherence, and open dialogue on COPD symptoms and functional status

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Barry J. Make, MD: Consultant/Advisor: AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Spiration, Inc; Sunovian Pharmaceuticals Inc.; Theravance Biopharma; Verona Pharma plc. Grant/Research Support: AstraZeneca. Speakers’ Bureau: AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Verona Pharma plc

Barbara P. Yawn, MD, MSc, FAAFP: Consultant/Advisor: AstraZeneca; GlaxoSmithKline plc. Employment Affiliation: Editor-in-Chief, Respiratory Medicine Case Reports

Non-faculty

Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from AstraZeneca.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education, American Association of Nurse Practitioners, and Integritas Communications

CME Credit (Physicians) 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP Credit (Nurses)

This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 0.25 contact hours of accredited education.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, American Association of Nurse Practitioners, Integritas Communications, and AstraZeneca do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. A physician who achieves a grade of 100% or better on the Post-Activity Test and who completes the Evaluation will receive a CME Certificate.
  6. All other participant who achieves a grade of 100% or better on the Post-Activity Test Questions and who completes the Evaluation will receive a Certificate of Participation.
Begin Activity